niacin

Summary

Summary: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.

Top Publications

  1. ncbi Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A
    Youyan Zhang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Biochem Biophys Res Commun 334:729-32. 2005
  2. pmc Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms
    Janet E Digby
    Department of Cardiovascular Medicine, John Radcliffe Hospital, and Sir William Dunn School of Pathology, University of Oxford, Oxford, OX3 9DU, UK
    Arterioscler Thromb Vasc Biol 32:669-76. 2012
  3. ncbi Niacin promotes cholesterol efflux through stimulation of the PPARgamma-LXRalpha-ABCA1 pathway in 3T3-L1 adipocytes
    Zhi hong Wu
    Department of Cardiology, Second Xiangya Hospital, Central South University, Hunan 410011, PR China
    Pharmacology 84:282-7. 2009
  4. ncbi Supplementing obese Zucker rats with niacin induces the transition of glycolytic to oxidative skeletal muscle fibers
    Robert Ringseis
    Institute of Animal Nutrition and Nutrition Physiology, Justus Liebig University, Giessen, Germany
    J Nutr 143:125-31. 2013
  5. pmc Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
    M John Chapman
    INSERM, UMR S939, Dyslipidemia, Inflammation and Atherosclerosis Research Unit, University Pierre and Marie Curie Paris 6, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Boulevard de l hopital, Paris Cedex 13, France
    Eur Heart J 31:149-64. 2010
  6. ncbi Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells
    Shobha H Ganji
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, CA 90822, United States
    Atherosclerosis 202:68-75. 2009
  7. pmc Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin
    Janet E Digby
    Department of Cardiovascular Medicine, University of Oxford, Oxford, United Kingdom
    Atherosclerosis 209:89-95. 2010
  8. pmc Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial
    Gregory C Shearer
    Sanford Research USD, University of South Dakota, Sioux Falls, SD, USA
    J Lipid Res 53:2429-35. 2012
  9. ncbi PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
    Sorin Tunaru
    Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
    Nat Med 9:352-5. 2003
  10. pmc Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells
    Martina Lukasova
    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    J Clin Invest 121:1163-73. 2011

Detail Information

Publications307 found, 100 shown here

  1. ncbi Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A
    Youyan Zhang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Biochem Biophys Res Commun 334:729-32. 2005
    A G-protein coupled receptor to niacin (nicotinic acid) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined...
  2. pmc Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms
    Janet E Digby
    Department of Cardiovascular Medicine, John Radcliffe Hospital, and Sir William Dunn School of Pathology, University of Oxford, Oxford, OX3 9DU, UK
    Arterioscler Thromb Vasc Biol 32:669-76. 2012
    ..We hypothesize that NA has the potential to act directly on monocytes to alter mediators of inflammation that may contribute to its antiatherogenic effects in vivo...
  3. ncbi Niacin promotes cholesterol efflux through stimulation of the PPARgamma-LXRalpha-ABCA1 pathway in 3T3-L1 adipocytes
    Zhi hong Wu
    Department of Cardiology, Second Xiangya Hospital, Central South University, Hunan 410011, PR China
    Pharmacology 84:282-7. 2009
    The mechanism by which niacin increases plasma levels of high-density lipoprotein cholesterol (HDL-C) is not clearly understood yet...
  4. ncbi Supplementing obese Zucker rats with niacin induces the transition of glycolytic to oxidative skeletal muscle fibers
    Robert Ringseis
    Institute of Animal Nutrition and Nutrition Physiology, Justus Liebig University, Giessen, Germany
    J Nutr 143:125-31. 2013
    In the present study, we tested the hypothesis that niacin increases the oxidative capacity of muscle by increasing the oxidative type I muscle fiber content...
  5. pmc Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
    M John Chapman
    INSERM, UMR S939, Dyslipidemia, Inflammation and Atherosclerosis Research Unit, University Pierre and Marie Curie Paris 6, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Boulevard de l hopital, Paris Cedex 13, France
    Eur Heart J 31:149-64. 2010
    ..e. statins, fibrates, and niacin, and compares their mechanisms of action with those of pharmacological agents under development which directly ..
  6. ncbi Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells
    Shobha H Ganji
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, CA 90822, United States
    Atherosclerosis 202:68-75. 2009
    In pharmacological doses, nicotinic acid (niacin) reduces myocardial infarction, stroke and atherosclerosis. The beneficial effects of niacin on lipoproteins are thought to mediate these effects...
  7. pmc Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin
    Janet E Digby
    Department of Cardiovascular Medicine, University of Oxford, Oxford, United Kingdom
    Atherosclerosis 209:89-95. 2010
    ....
  8. pmc Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial
    Gregory C Shearer
    Sanford Research USD, University of South Dakota, Sioux Falls, SD, USA
    J Lipid Res 53:2429-35. 2012
    The metabolic syndrome includes both dyslipidemia and impaired vascular function. Because extended-release niacin (ERN) and prescription omega-3 acid ethyl-esters (P-OM3) independently improve these characteristics, we tested their ..
  9. ncbi PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
    Sorin Tunaru
    Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
    Nat Med 9:352-5. 2003
    Nicotinic acid (niacin), a vitamin of the B complex, has been used for almost 50 years as a lipid-lowering drug. The pharmacological effect of nicotinic acid requires doses that are much higher than those provided by a normal diet...
  10. pmc Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells
    Martina Lukasova
    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    J Clin Invest 121:1163-73. 2011
    Nicotinic acid (niacin) is a drug used to reduce the progression of atherosclerosis...
  11. ncbi Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
    Eric Bruckert
    Department of Endocrinology, Pitie Salpetriere University Hospital, Pierre and Marie Curie University, 83 bd de l hopital, 75651, Paris, France
    Atherosclerosis 210:353-61. 2010
    ....
  12. ncbi The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration
    Todd C Villines
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC 20307, USA
    J Am Coll Cardiol 55:2721-6. 2010
    ..This report describes the final results of the ARBITER 6-HALTS (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) trial...
  13. ncbi Niaspan increases angiogenesis and improves functional recovery after stroke
    Jieli Chen
    Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Ann Neurol 62:49-58. 2007
    High-density lipoprotein (HDL) is implicated in the modulation of angiogenesis. In this study, we investigated whether the Niacin-mediated increase of HDL regulates angiogenesis and thereby improves functional outcome after stroke.
  14. ncbi Why do some yeast species require niacin for growth? Different modes of NAD synthesis
    You Fang Li
    CNRS UMR 8621, Institut de Genetique et Microbiologie, Universite Paris Sud 11, Orsay, France
    FEMS Yeast Res 7:657-64. 2007
    ..lactis. The results suggested that the basis of the variation of niacin requirements in yeasts lies in their different combinations of NAD biosynthesis pathways...
  15. pmc GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon
    Muthusamy Thangaraju
    Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia 30912, USA
    Cancer Res 69:2826-32. 2009
    ..These studies show that GPR109A mediates the tumor-suppressive effects of the bacterial fermentation product butyrate in colon...
  16. ncbi GPR109A as an anti-inflammatory receptor in retinal pigment epithelial cells and its relevance to diabetic retinopathy
    Deeksha Gambhir
    Department of Biochemistry and Molecular Biology, and the Vision Science Discovery Institute, Georgia Health Sciences University, Augusta, Georgia 30912, USA
    Invest Ophthalmol Vis Sci 53:2208-17. 2012
    Retinal pigment epithelium (RPE) expresses GPR109A, a receptor for the vitamin niacin and the ketone body β-hydroxybutyrate (β-HB)...
  17. ncbi Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
    B G Brown
    Department of Medicine, University of Washington School of Medicine, Seattle 98195, USA
    N Engl J Med 345:1583-92. 2001
    ..We studied simvastatin-niacin and antioxidant-vitamin therapy, alone and together, for cardiovascular protection in patients with coronary ..
  18. pmc Widespread effects of nicotinic acid on gene expression in insulin-sensitive tissues: implications for unwanted effects of nicotinic acid treatment
    Sangdun Choi
    Department of Molecular Science and Technology, Ajou University, Suwon, South Korea
    Metabolism 60:134-44. 2011
    Nicotinic acid (NA; or niacin) has been used as a hypolipidemic agent for more than 4 decades. However, the mechanisms underlying the effects of NA treatment (wanted and unwanted) are still poorly understood...
  19. ncbi Niacin status, NAD distribution and ADP-ribose metabolism
    James B Kirkland
    Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada N1G 2W1
    Curr Pharm Des 15:3-11. 2009
    Dietary niacin deficiency, and pharmacological excesses of nicotinic acid or nicotinamide, have dramatic effects on cellular NAD pools, ADP-ribose metabolism, tissue function and health...
  20. ncbi Niacin: the evidence, clinical use, and future directions
    Todd C Villines
    Cardiology Service, Department of Medicine, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD 20889, USA
    Curr Atheroscler Rep 14:49-59. 2012
    The use of FDA-approved niacin (nicotinic acid or vitamin B3) formulations at therapeutic doses, alone or in combination with statins or other lipid therapies, is safe, improves multiple lipid parameters, and reduces atherosclerosis ..
  21. ncbi Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways
    Helen J Knowles
    Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Biochem Pharmacol 71:646-56. 2006
    HM74 and HM74a have been identified as receptors for niacin. HM74a mediates the pharmacological anti-lipolytic effects of niacin in adipocytes by reducing intracellular cyclic AMP (cAMP) and inhibiting release of free fatty acids into the ..
  22. ncbi Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Ou
    Erin D Michos
    The Johns Hopkins University School of Medicine, Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland 21287, USA
    J Am Coll Cardiol 59:2058-64. 2012
    ..Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial, which compared combined niacin/simvastatin with simvastatin alone, failed to demonstrate an incremental benefit of niacin among patients with ..
  23. ncbi Extended-release niacin or ezetimibe and carotid intima-media thickness
    Allen J Taylor
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA
    N Engl J Med 361:2113-22. 2009
    ....
  24. pmc Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib
    Laurent Yvan-Charvet
    Division of Molecular Medicine, Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032, USA
    Arterioscler Thromb Vasc Biol 30:1430-8. 2010
    To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on the ability of high-density lipoprotein (HDL) to promote net cholesterol efflux and reduce toll-like receptor-mediated ..
  25. pmc Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice
    Julien Hanson
    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    J Clin Invest 120:2910-9. 2010
    ..These data will help to guide new efficient approaches to mitigate nicotinic acid-induced flushing and may help to exploit the potential antipsoriatic effects of GPR109A agonists in the skin...
  26. ncbi Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids
    Ben J Wu
    Lipid Research Group, Heart Research Institute, 7 Eliza St, Newtown, New South Wales, Australia 2042
    Arterioscler Thromb Vasc Biol 30:968-75. 2010
    To determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels.
  27. ncbi Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury
    Suresh Varma Penumathsa
    Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 1110, USA
    Biochim Biophys Acta 1792:39-48. 2009
    ..We investigated the effect of niacin-bound chromium (NBC) during ischemia/reperfusion (IR) injury in streptozotocin induced diabetic rats...
  28. ncbi Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits
    Shui Ping Zhao
    Department of Cardiology, The Second Xiangya Hospital of Central South University, Middle Ren Min Road No 86, Changsha, Hunan 410011, PR China
    Int J Cardiol 124:172-8. 2008
    ..The aim of this study was to evaluate the effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes from hypercholesterolemic ..
  29. pmc beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice
    Robert W Walters
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    J Clin Invest 119:1312-21. 2009
    ..Furthermore, G protein-biased ligands that activate GPR109A in a beta-arrestin-independent fashion may represent an improved therapeutic option for the treatment of dyslipidemia...
  30. ncbi Molecular identification of high and low affinity receptors for nicotinic acid
    Alan Wise
    Department of 7TMR Systems Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
    J Biol Chem 278:9869-74. 2003
    ..The discovery of HM74A as a molecular target for nicotinic acid may facilitate the discovery of superior drug molecules to treat dyslipidemia...
  31. ncbi Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study
    Ascan Warnholtz
    Department of Medicine II, Johannes Gutenberg University Mainz, Mainz, Germany
    Atherosclerosis 204:216-21. 2009
    ..Recent studies suggest that HDL-C directly improves endothelial function. Nicotinic acid (niacin) effectively raises serum HDL-C...
  32. pmc Niacin treatment of stroke increases synaptic plasticity and axon growth in rats
    Xu Cui
    Department of Neurology, Henry Ford Hospital, Detroit, Mich 48202, USA
    Stroke 41:2044-9. 2010
    b>Niacin is the most effective medication in current clinical use for increasing high-density lipoprotein cholesterol...
  33. ncbi Change in alpha1 HDL concentration predicts progression in coronary artery stenosis
    Bela F Asztalos
    Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Center on Aging at Tufts University and Division of Endocrinology, Metabolism, Diabetes, and Molecular Medicine, New England Medical Center, Boston, Mass 02111, USA
    Arterioscler Thromb Vasc Biol 23:847-52. 2003
    We examined the effects of simvastatin-niacin and antioxidant vitamins on changes in high-density lipoprotein (HDL) subpopulations and alterations in coronary artery stenosis, as assessed by angiography.
  34. ncbi Niacin in cardiovascular prevention: mechanisms, efficacy, and safety
    John R Guyton
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Lipidol 18:415-20. 2007
    This review describes niacin's mechanism of action, efficacy in cardiovascular prevention, and safety.
  35. pmc Comparative genomics of NAD biosynthesis in cyanobacteria
    Svetlana Y Gerdes
    Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Bacteriol 188:3012-23. 2006
    ..generated nicotinamide, as supported by the inability of this organism to utilize exogenously provided niacin. Positional clustering and the co-occurrence profile of the respective genes across a diverse collection of ..
  36. ncbi Extended-release niacin raises adiponectin and leptin
    Sabine Westphal
    Institute of Clinical Chemistry, Magdeburg University Hospital, Leipziger Str 44, D 39120 Magdeburg, Germany
    Atherosclerosis 193:361-5. 2007
    The lipid-lowering drug niacin has attracted renewed interest because it raises HDL-cholesterol and because it has recently been found to slow down the progression of intima media thickness in patients with coronary heart disease...
  37. ncbi Niacin and cholesterol: role in cardiovascular disease (review)
    Shobha H Ganji
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, California, USA
    J Nutr Biochem 14:298-305. 2003
    b>Niacin has been widely used as a pharmacologic agent to regulate abnormalities in plasma lipid and lipoprotein metabolism and in the treatment of atherosclerotic cardiovascular disease...
  38. ncbi Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis
    Nagendra Singh
    Department of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA Cancer Research Center, Georgia Regents University, Augusta, GA 30912, USA Electronic address
    Immunity 40:128-39. 2014
    ..GPR109A (encoded by Niacr1) is a receptor for butyrate in the colon. GPR109A is also a receptor for niacin, which is also produced by gut microbiota and suppresses intestinal inflammation...
  39. ncbi The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression
    Paul M Lavigne
    Molecular Cardiology Research Institute, Division of Cardiology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 61:440-6. 2013
    This study sought to assess the efficacy of niacin for reducing cardiovascular disease (CVD) events, as indicated by the aggregate body of clinical trial evidence including data from the recently published AIM-HIGH (Atherothrombosis ..
  40. pmc Intravenous niacin acutely improves the efficiency of dietary fat storage in lean and obese humans
    Robert H Nelson
    Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota, USA
    Diabetes 61:3172-5. 2012
    ..overweight and obese (n = 5) subjects during continuous feeding on two occasions: during intravenous infusion of niacin (2.8 mg/min) and saline...
  41. ncbi Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice
    Zhaosha Li
    Division of Biopharmaceutics, Leiden Amsterdam Center for Drug Research, Leiden University, The Netherlands
    Biochem Pharmacol 84:821-9. 2012
    The anti-dyslipidemic drug niacin has recently been shown to reduce the hepatic expression and plasma levels of CETP...
  42. pmc Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois College of Medicine, Peoria, CGH Medical Center, 101 East Miller Road, Sterling, IL 61081, USA
    Vasc Health Risk Manag 8:39-44. 2012
    The purpose of this research was to compare the effects of niacin extended-release in combination with simvastatin (NER/S) versus atorvastatin monotherapy on high-density lipoprotein (HDL) particle number and size in patients with ..
  43. pmc Niaspan increases axonal remodeling after stroke in type 1 diabetes rats
    Tao Yan
    Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China
    Neurobiol Dis 46:157-64. 2012
    ..We investigated axonal plasticity in the bilateral motor cortices and the long term therapeutic effect of Niaspan on axonal remodeling after stroke in type-1 diabetic (T1DM) rats...
  44. ncbi Niacin inhibits vascular inflammation via the induction of heme oxygenase-1
    Ben J Wu
    Lipid Research Group, The Heart Research Institute, 7 Eliza St, Newtown, NSW, Australia, 2042
    Circulation 125:150-8. 2012
    ..b>Niacin is a pleiotropic drug that slows the progression of coronary artery disease and increases serum levels of the HO-1 ..
  45. ncbi Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials
    Martina Lukasova
    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Ludwigstrasse 43, 61231 Bad Nauheim, Germany
    Trends Pharmacol Sci 32:700-7. 2011
    Nicotinic acid (niacin) has been used for decades to prevent and treat atherosclerosis...
  46. pmc Niacin increases adiponectin and decreases adipose tissue inflammation in high fat diet-fed mice
    Desiree Wanders
    Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA
    PLoS ONE 8:e71285. 2013
    To determine the effects of niacin on adiponectin and markers of adipose tissue inflammation in a mouse model of obesity.
  47. ncbi Increased total and high-molecular weight adiponectin after extended-release niacin
    Eric P Plaisance
    Department of Anatomy, Physiology and Pharmacology, Boshell Diabetes and Metabolic Diseases Research Program, Auburn University, Auburn, AL 36849, USA
    Metabolism 57:404-9. 2008
    b>Niacin has recently been shown to increase serum total concentrations of the adipocyte-derived protein adiponectin...
  48. ncbi The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome
    M Thoenes
    Institut fur Klinische Pharmakologie, Technische Universitat Dresden, Dresden, Germany
    Int J Clin Pract 61:1942-8. 2007
    b>Niacin is an agent that significantly increases high-density lipoprotein cholesterol (HDL-C), but its effects on surrogate markers of atherosclerosis and inflammatory markers are less clear...
  49. ncbi Recent advances in niacin and lipid metabolism
    Vaijinath S Kamanna
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, California 90822, USA
    Curr Opin Lipidol 24:239-45. 2013
    This review focuses on the current understanding of the physiological mechanisms of action of niacin on lipid metabolism and atherosclerosis.
  50. ncbi Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy
    Vummidi Giridhar Premkumar
    Department of Medical Biochemistry, DR A L M Post Graduate, Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, Tamil Nadu, India
    Br J Nutr 100:1179-82. 2008
    ..cancer patients were randomized to receive a daily supplement of 100 mg co-enzyme Q10, 10 mg riboflavin and 50 mg niacin (CoRN), one dosage per d along with 10 mg tamoxifen twice per d...
  51. pmc Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells
    Lin Hua Zhang
    Atherosclerosis Research Center, Veterans Affairs Healthcare System, Long Beach, CA, USA
    J Lipid Res 53:941-50. 2012
    ..b>Niacin is the most effective lipid-regulating agent clinically available to raise HDL...
  52. ncbi Adipokines and treatment with niacin
    Sabine Westphal
    Institute of Clinical Chemistry, Magdeburg University Hospital, D 39120 Magdeburg, Germany
    Metabolism 55:1283-5. 2006
    ..Because adipose tissue is one site of action of the lipid-lowering drug niacin, we investigated whether niacin treatment would affect not only lipids but also adipokines...
  53. ncbi Effects of dietary di(2-ethylhexyl)phthalate, a putative endocrine disrupter, on enzyme activities involved in the metabolism of tryptophan to niacin in rats
    Tsutomu Fukuwatari
    Laboratories of Food Science and Nutrition, Department of Life Style Studies, School of Human Cultures, The University of Shiga Prefecture, 2500 Hassaka cho, Hikone, Shiga, 522 8533, Japan
    Biochim Biophys Acta 1672:67-75. 2004
    We have reported that the conversion ratio of tryptophan to niacin increased with increasing dietary concentration of di(2-ethylhexyl)phthalate (DEHP); the conversion ratio was about 2...
  54. ncbi Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy
    Sajoscha A Sorrentino
    Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Germany
    Circulation 121:110-22. 2010
    ..Moreover, in diabetic patients, we examined the impact of extended-release (ER) niacin therapy on the endothelial effects of HDL.
  55. ncbi Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study
    Vasu Babu Ravi
    Research Studies, Rayalaseema University, Kurnool 518 002, India
    Biomed Chromatogr 26:1436-43. 2012
    ..and selective LC-MS/MS method has been developed and validated for quantification of the atorvastatin (AT) and niacin (NA) in 250 μL human plasma...
  56. ncbi Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL
    M C Cheung
    Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, School of Medicine, University of Washington, Seattle 98103, USA
    Arterioscler Thromb Vasc Biol 21:1320-6. 2001
    ..low HDL cholesterol (HDL-C) is to maximally increase the HDL-C to LDL-C ratio by combining lifestyle changes with niacin (N) plus a statin...
  57. ncbi Safety and toxicological evaluation of a novel niacin-bound chromium (III) complex
    Michael Shara
    Creighton University Medical Center, Omaha, NE, USA
    J Inorg Biochem 99:2161-83. 2005
    ..It also helps in energy production and increasing lean body mass. Niacin-bound chromium (NBC) is a unique form of bioavailable chromium that promotes healthy lipid profile...
  58. pmc Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2
    Allen J Taylor
    Cardiology Service, Walter Reed Army Medical Center, 6900 Georgia Avenue, NW, Building 2, Room 4A34, Washington, DC 20307 5001, USA
    Vasc Health Risk Manag 3:159-64. 2007
    We previously reported in a placebo-controlled study that extended-release niacin slowed the progression of carotid atherosclerosis when added to statin monotherapy...
  59. ncbi Langerhans cells release prostaglandin D2 in response to nicotinic acid
    Dominique Maciejewski-Lenoir
    Arena Pharmaceuticals Inc, San Diego, California 92121, USA
    J Invest Dermatol 126:2637-46. 2006
    ..These results suggest that nicotinic acid mediates its flushing side effect by interacting with GPR109A on skin Langerhans cells, resulting in release of PGD(2)...
  60. ncbi Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush
    C Daniel Meyers
    Long Beach Veterans Affairs Healthcare System, Long Beach, CA, United States
    Atherosclerosis 192:253-8. 2007
    ..shown to prevent cardiovascular disease, yet its widespread use is limited by the prostaglandin D2 (PGD2) mediated niacin flush...
  61. pmc Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
    Klaus G Parhofer
    Medical Department II Grosshadern, University of Munich, Germany
    Vasc Health Risk Manag 5:901-8. 2009
    ..b>Niacin (nicotinic acid) is an effective drug which increases the plasma concentration of high-density lipoprotein (HDL)-..
  62. ncbi Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia
    S Shah
    Merck Research Laboratories, Cardiovascular Disease, Merck, Sharp and Dohme Corp, Rahway, NJ 07065, USA
    Int J Clin Pract 64:727-38. 2010
    Co-administration of niacin with statin offers the potential for additional lipid management and cardiovascular risk reduction...
  63. ncbi Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease
    Jasleen K Duggal
    Chicago Medical School and Affiliated Hospitals, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
    J Cardiovasc Pharmacol Ther 15:158-66. 2010
    b>Niacin or nicotinic acid (vitamin B3) raises the levels of high-density lipoprotein cholesterol (HDL) by about 30% to 35%...
  64. ncbi Niacin therapy in atherosclerosis
    C Daniel Meyers
    Endocrinology Section, VA Long Beach Healthcare System, Department of Medicine, University of California, Irvine, California, USA
    Curr Opin Lipidol 15:659-65. 2004
    Well designed, randomized, placebo-controlled studies show that niacin prevents cardiovascular disease and death...
  65. ncbi Aerobic and anaerobic NAD+ metabolism in Saccharomyces cerevisiae
    Cristina Panozzo
    Centre de Genetique Moleculaire, Laboratoire propre du CNRS, associé à l Université Pierre et Marie Curie, Gif sur Yvette, France
    FEBS Lett 517:97-102. 2002
    ..cerevisiae. Also, we show that under anaerobic conditions S. cerevisiae is a nicotinic acid auxotroph...
  66. pmc High-affinity transporters for NAD+ precursors in Candida glabrata are regulated by Hst1 and induced in response to niacin limitation
    Biao Ma
    Department of Molecular Biology and Genetics, Johns Hopkins School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205 2185, USA
    Mol Cell Biol 29:4067-79. 2009
    ..C. glabrata is a NAD(+) auxotroph, and its growth depends on the availability of niacin (environmental vitamin precursors of NAD(+))...
  67. ncbi The nicotinic acid receptor--a new mechanism for an old drug
    Fredrik Karpe
    Oxford Centre for Diabetes, Endocrinology and Metabolism, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Lancet 363:1892-4. 2004
    ..Suppression of lipolysis by nicotinic acid gives rise to a prominent rebound and the degree to which this occurs might explain this paradox...
  68. ncbi Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure
    Kyu hyang Cho
    Division of Nephrology and Hypertension, University of California, Irvine, California, USA
    Am J Physiol Renal Physiol 297:F106-13. 2009
    ..b>Niacin is known to improve lipid metabolism and exert antioxidant/anti-inflammatory actions...
  69. ncbi Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study
    Justin M S Lee
    Department of Cardiovascular Medicine, University of Oxford and Oxford Centre for Clinical Magnetic Resonance Research OCMR, Oxford, United Kingdom
    J Am Coll Cardiol 54:1787-94. 2009
    ..Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function...
  70. ncbi Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
    M John Chapman
    Dyslipidemia, Inflammation and Atherosclerosis Research Unit, UMR S939, National Institute for Health and Medical Research INSERM, Hopital de la Pitie Salpetriere, Paris, France
    Pharmacol Ther 126:314-45. 2010
    ..In this context, there is renewed interest in pharmacotherapeutic strategies involving niacin and fibrates in monotherapy and in association with statins...
  71. ncbi Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells
    Shobha H Ganji
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, CA, USA
    J Lipid Res 45:1835-45. 2004
    b>Niacin is a widely used lipid-regulating agent in dyslipidemic patients. Previously, we have shown that niacin inhibits triacylglycerol synthesis...
  72. pmc Combined statin and niacin therapy remodels the high-density lipoprotein proteome
    Pattie S Green
    Department of Medicine, University of Washington, Seattle, WA, USA
    Circulation 118:1259-67. 2008
    ..We hypothesized that an intervention that increases HDL levels-combined statin and niacin therapy-might reverse these changes.
  73. ncbi Nicotinic acid: pharmacological effects and mechanisms of action
    Andreas Gille
    Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
    Annu Rev Pharmacol Toxicol 48:79-106. 2008
    ....
  74. pmc Niacin restriction upregulates NADPH oxidase and reactive oxygen species (ROS) in human keratinocytes
    Claudia A Benavente
    Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Free Radic Biol Med 44:527-37. 2008
    ..Removal of niacin from the cell culture medium allowed control of intracellular NAD...
  75. ncbi Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview
    Sachin Kamal-Bahl
    Merck and Co, Inc, West Point, Pennsylvania, USA
    Clin Ther 31:130-40. 2009
    b>Niacin is highly effective at raising high-density lipoprotein cholesterol but remains underused because of the adverse event of flushing.
  76. ncbi Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model
    Dean Papaliodis
    Department of Pharmacology and Experimental Therapeutics, Molecular Immunopharmacology and Drug Discovery Laboratory, Tufts University School of Medicine, Tufts Medical Center, Boston, MA 02111, USA
    J Pharmacol Exp Ther 327:665-72. 2008
    b>Niacin lowers serum cholesterol, low-density lipoprotein, and triglycerides, and it raises high-density lipoprotein. However, most patients experience cutaneous warmth and vasodilation (flush)...
  77. ncbi A topical lipophilic niacin derivative increases NAD, epidermal differentiation and barrier function in photodamaged skin
    Elaine L Jacobson
    Department of Pharmacology and Toxicology, College of Pharmacy, Tucson, AZ 85724, USA
    Exp Dermatol 16:490-9. 2007
    ....
  78. ncbi Nicotinic acid and the prevention of coronary artery disease
    Janet E Digby
    Department of Cardiovascular Medicine, University of Oxford, Oxford, UK
    Curr Opin Lipidol 20:321-6. 2009
    ..at all levels of LDL cholesterol has, therefore, given renewed emphasis on the therapeutic potential of niacin. The purpose of this review is to evaluate advances in the elucidation of mechanisms by which nicotinic acid ..
  79. pmc Chronic niacin overload may be involved in the increased prevalence of obesity in US children
    Da Li
    Institute of Basic Medical Sciences, Medical College, Dalian University, Dalian 116622, Liaoning Province, China
    World J Gastroenterol 16:2378-87. 2010
    To investigate nicotinamide's action on glucose metabolism, and the association between niacin consumption and obesity prevalence.
  80. ncbi Niacin stimulates adiponectin secretion through the GPR109A receptor
    Eric P Plaisance
    Department of Anatomy, Auburn University, Auburn, AL 36849, USA
    Am J Physiol Endocrinol Metab 296:E549-58. 2009
    b>Niacin (nicotinic acid) has recently been shown to increase serum adiponectin concentrations in men with the metabolic syndrome...
  81. ncbi Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects
    Crystal A Gadegbeku
    Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
    Am J Hypertens 16:67-71. 2003
    ..The adjustment in vascular compliance may be an important factor in determining overall BP response to NA...
  82. ncbi Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients
    Daniela Muller
    Franz Volhard Clinic, Department of Nephrology and Hypertension, Medical Faculty of the Charite, HELIOS Klinikum Berlin, Berlin, Germany
    Clin J Am Soc Nephrol 2:1249-54. 2007
    ..Adverse effects complicate the use of drugs that are prescribed for phosphate control in dialysis patients. Alternative treatment options are needed...
  83. pmc Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatm
    Binh An P Phan
    Division of Cardiology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA
    Am J Cardiol 111:352-5. 2013
    Although the effect of niacin on the glucose levels in subjects with diabetes mellitus has been investigated, niacin's effects on the glucose levels and atherosclerosis in subjects with normal glucose levels have not been well established...
  84. ncbi Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic rats
    Sema Bolkent
    Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, 34300 Cerrahpaşa, Istanbul, Turkey
    Biol Trace Elem Res 101:219-29. 2004
    Many studies have shown that niacin and Cr exert combined effects. Significant beneficial effects in serum lipid levels following Cr supplementation have been reported...
  85. pmc Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin
    Jennifer G Robinson
    University of Iowa, Iowa City, IA, USA
    Vasc Health Risk Manag 5:31-43. 2009
    ER niacin combined with simvastatin provides an additional option for achieving LDL-C and non-HDL-C goals for cardiovascular prevention, with greater efficacy in those with triglyceride levels >200 mg/dL...
  86. ncbi Niacin: chemical forms, bioavailability, and health effects
    Douglas MacKay
    Council for Responsible Nutrition, Washington, DC 20036, USA
    Nutr Rev 70:357-66. 2012
    ..b>Niacin is considered a valuable agent for therapy to modify high LDL-C as well as low HDL-C, high lipoprotein a, and ..
  87. ncbi The benefits of niacin in atherosclerosis
    S Tavintharan
    Cholesterol Research Center, Department of Veterans Affairs Healthcare System, University of California, Irvine, 5901 East Seventh Street (11/111-I) Long Beach, CA 90822, USA
    Curr Atheroscler Rep 3:74-82. 2001
    b>Niacin favorably alters all major lipid subfractions at pharmacologic doses. Alone or in combination, it promotes regression of coronary artery disease, decreases coronary events, stroke, and total mortality...
  88. ncbi Effects of encapsulated niacin on metabolism and production of periparturient dairy cows
    S D Morey
    Department of Animal Sciences and Industry, Kansas State University, Manhattan 66506, USA
    J Dairy Sci 94:5090-104. 2011
    Nicotinic acid (niacin) can suppress lipolysis, but responses to dietary niacin have been inconsistent in cattle. Our aim was to determine if 24 g/d of encapsulated niacin (EN; providing 9...
  89. ncbi Niacin attenuates lung inflammation and improves survival during sepsis by downregulating the nuclear factor-κB pathway
    Woon Yong Kwon
    Department of Emergency Medicine, Seoul National University College of Medicine, Seoul, Korea
    Crit Care Med 39:328-34. 2011
    To examine whether niacin attenuates lung inflammation and improves survival during sepsis and to determine whether the beneficial effects of niacin are associated with downregulation of the nuclear factor (NF)-κB pathway.
  90. ncbi Quercetin with vitamin C and niacin does not affect body mass or composition
    Amy M Knab
    North Carolina Research Campus, Human Performance Laboratory, Kannapolis, NC 28081, USA
    Appl Physiol Nutr Metab 36:331-8. 2011
    ..This study investigated 12-week supplementation of 2 different doses of quercetin, combined with vitamin C and niacin, on body mass and composition in a large, heterogeneous group of adults (n = 941; 60% female, 40% male; 18-85 ..
  91. ncbi Niacin status impacts chromatin structure
    James B Kirkland
    Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada
    J Nutr 139:2397-401. 2009
    b>Niacin is required to form NAD and NADP, which are involved in many essential redox reactions in cellular metabolism...
  92. ncbi Optical coherence tomography findings in niacin maculopathy
    Hatem Marwan Dajani
    The School of Medicine, Oregon Health and Science University, and the Devers Eye Institute, Legacy Hospitals, Portland, OR 97239 4197, USA
    Can J Ophthalmol 41:197-200. 2006
    We present the case of 54-year-old male who developed bilateral cystoid macular thickening while taking 3 g of niacin per day, and we describe the optical coherence tomography (OCT) features of niacin (nicotinic acid) maculopathy.
  93. pmc Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes
    Xiaoyu Li
    Institute for Translational Medicine and Therapeutics and Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
    Biochem Pharmacol 80:1450-7. 2010
    The niacin receptor GPR109A is a G(i)-protein-coupled receptor which mediates the effects of niacin on inhibiting intracellular triglyceride lipolysis in adipocytes...
  94. ncbi Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome
    Shalini V Kaushik
    Department of Nutrition and Food Science, Auburn University, Auburn, AL 36849, USA
    Diabetes Metab Res Rev 25:427-34. 2009
    ..The goal of this study was to determine the effect of niacin administration on serum total- and phosphorylated fetuin-A (phosphofetuin-A) concentrations in individuals with ..
  95. ncbi Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man
    Virpi Saareks
    Department of Pharmacological Sciences, University of Tampere, Finland
    Pharmacol Toxicol 90:338-42. 2002
    ....
  96. ncbi Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial
    Mark S Nash
    Department of Neurological Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA
    Arch Phys Med Rehabil 92:399-410. 2011
    To test the safety, tolerance, and efficacy of extended-release niacin monotherapy on dyslipidemia in persons with chronic tetraplegia.
  97. ncbi Niacin subsensitivity is associated with functional impairment in schizophrenia
    Erik Messamore
    Behavioral Health and Clinical Neurosciences Division, Portland VA Medical Center, Portland, OR 97239, USA
    Schizophr Res 137:180-4. 2012
    Sensitivity to the skin flush effect of niacin is reduced in a portion of patients with schizophrenia...
  98. ncbi Induction of differentiation in human promyelocytic leukemia HL-60 cell line by niacin-related compounds
    Keiko Iwata
    Laboratory of Molecular and Cellular Biology, Department of Life Science, Faculty of Bioresources, Mie University, Tsu, Mie 514 8507, Japan
    Biosci Biotechnol Biochem 67:1132-5. 2003
    Water-soluble vitamin, niacin, and its related compounds were examined for their differentiation-inducing activity in human promyelocytic leukemia cells (HL-60)...
  99. ncbi Niacin promotes adipogenesis by reducing production of anti-adipogenic PGF2α through suppression of C/EBPβ-activated COX-2 expression
    Ko Fujimori
    Laboratory of Biodefense and Regulation, Osaka University of Pharmaceutical Sciences, 4 20 1 Nasahara, Takatsuki, Osaka 569 1094, Japan
    Prostaglandins Other Lipid Mediat 94:96-103. 2011
    b>Niacin is converted to NAD and NADP in tissues, whose products are involved in a number of cellular processes; and it is associated with the regulation of adipogenesis...

Research Grants62

  1. Novel mechanisms of niacin to improve HDL function: Role of myeloperoxidase
    Moti L Kashyap; Fiscal Year: 2013
    ..Nicotinic acid (Niacin) is a widely used agent in the treatment of dyslipidemia, and clinical trials indicate that the treatment with ..
  2. A Trial of Zinc and Micronutrients in Tanzanian Children
    Christopher P Duggan; Fiscal Year: 2010
    ..be recruited and randomly assigned in a factorial design to either zinc, micronutrients (vitamins C, E, B1, B2, niacin, B6, folate, and B12) plus zinc, micronutrients without zinc, or a placebo given daily...
  3. A Novel Approach to Phosphorus Lowering in Patients with Chronic Kidney Disease
    Joachim H Ix; Fiscal Year: 2013
    ..The lipid drug niacin contains both nicotinamide and nicotinic acid, and we have shown that it lowers Pi in CKD patients...
  4. CHEMOPREVENTION OF SKIN CANCER PROGRAM PROJECT
    George Timothy Bowden; Fiscal Year: 2013
    ..abstract_text> ..
  5. FFA Production From Triglyceride-Rich Lipoproteins
    John M Miles; Fiscal Year: 2013
    ..Subsequent studies have shown that intravenous infusion of niacin, a drug known to suppress FFA release, produced a significant reduction in fractional spillover, whereas insulin ..
  6. Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis
    Emmanouil Brilakis; Fiscal Year: 2013
    ..b>Niacin raises HDL-C, restores the re-endothelialization capacity of EPCs, and slowed the progression of SVG ..
  7. Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia
    Christie G Brouillette; Fiscal Year: 2010
    ..These diseases are caused by three of the highest risk bacterial bioterrorism agents, B. anthracis, Y. pestis, and F. tularensis. ..
  8. ENZYMATIC REACTIONS OF PLASMA LIPOPROTEINS
    Henry J Pownall; Fiscal Year: 2010
    ..Although niacin and the statin class of hypolipidemic drugs can increase HDL-C, their effects are modest and better HDL therapies ..
  9. Niacin-mediated migration of monocyte-derived cells in atherosclerosis
    MOLLY INGERSOLL; Fiscal Year: 2010
    ..protocol to trace migration of monocyte subsets in mouse atherosclerotic plaques, demonstrated that intake of 1% niacin supplemented diet promoted monocyte-derived cell egress from plaques rescuing monocytes from dying in necrotic ..
  10. Mechanism of HPA Axis Activation: Role of Nicotinic Acid Receptor in the Brain
    Jang H Youn; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Nicotinic acid (NA;or niacin) is a water-soluble vitamin...
  11. Niacin therapy to improve endothelial function in Sickle Cell Disease
    NAOMI L LUBAN; Fiscal Year: 2011
    ..We propose a forearm blood flow physiology study with Niaspan, a slow release form of niacin, previously reported to increase high density lipoprotein (HDL) and apo A-l levels...
  12. Phospholipid-Arachidonate-Eicosanoid Signaling in Schizophrenia
    Jeffrey K Yao; Fiscal Year: 2013
    ..Further, we propose that phospholipid-arachidonate-eicosanoid (PAE) signaling abnormalities are responsible for niacin subsensitivity (the reduced sensitivity to the skin flush effect of niacin), which is among the most widely-..
  13. AIM-HIGH
    RUTH M MCBRIDE; Fiscal Year: 2010
    ..controlled clinical trial designed to test the hypothesis that the drug combination of extended-release (ER-) niacin plus simvastatin is superior to simvastatin alone, at comparable levels of intreatment LDL-cholesterol, for ..
  14. Niacin's effect on fatty acids and inflammatory markers (NEFA-IM)
    RICHARD LOUIS DUNBAR; Fiscal Year: 2012
    ..Specific hypotheses related to Niacin's Effects on Fatty Acids and Inflammatory Markers (NEFA-IM) are assessed using a niacin challenge to provoke ..
  15. AIM HIGH: Niacin Plus Statin to Prevent Vascular Events
    JEFFREY LYNN PROBSTFIELD; Fiscal Year: 2010
    AIM-HIGH is a multicenter controlled clinical trial designed to test whether the drug combination extended release niacin plus simvastatin is superior to simvastatin alone, at comparable levels of in-treatment LDLcholesterol (LDL-C), for ..
  16. Elucidation of Tissue-Specific Transcriptomic Profiles in Cardiometabolic Disease
    Muredach P Reilly; Fiscal Year: 2013
    ..In the Genetics of Evoked-Responses to Niacin and Endotoxemia (GENE) study, we recruited healthy individuals (N=286) to an inpatient protocol and collected ..
  17. Effects of Niacin on Lp(a), Oxidized LDL, and inflammation in the AIM-HIGH trial
    DANIEL JAMES RADER; Fiscal Year: 2013
    ..therapy (to raise HDL-C and lower both triglycerides and LDL-C) with simvastatin plus extended- release niacin (niacin) will reduce cardiovascular events more than LDL-lowering alone with simvastatin in patients with ..
  18. Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
    KEVIN DOUGLAS O'BRIEN; Fiscal Year: 2012
    ..changes in HDL that are associated with impairment of its normal function but that are improved with statin+niacin therapy...
  19. DOES ATHEROSCLEROSIS REGRESS WITH THERAPY FOR LOW HDLC?
    Bruce Brown; Fiscal Year: 2000
    ..o.) and women (less than 67 y.o.) to double-blinded therapy, assigned in a factorial design: 1) mid-dose niacin (500 mg qid), plus simvastatin (20 mg qd); 2) an antioxidant cocktail (vitamin C (500 mg bid), E (400 IU bid), and ..
  20. FUNCTIONAL CHARACTERISTICS OF THE LEFT HEART
    HAROLD DODGE; Fiscal Year: 1990
    ..natural history of coronary atherosclerotic lesions and the effect of serum lipid lowering with colestepol plus niacin or mevinolin and also cholestyramine on the rate of lesion progression...
  21. BIOSYNTHESIS OF VITAMIN B1 AND VITAMIN B6
    IAN SPENSER; Fiscal Year: 2000
    ..coli, since other Vitamins (e.g., thiamin, niacin) have distinct modes of origin in prokaryotes and eukaryotes...
  22. PROCESSING OF NUTRITIONAL ASPECTS OF BREAST MILK
    KHEM SHAHANI; Fiscal Year: 1980
    ..to the effects of slow freezing, quick freezing and freeze dehydration and storage upon certin B vitamins (niacin, biotin and pantothenic acid), enzymes such as protease, lysozyme, lipase and lactoperoxidase, and several lipid ..
  23. Niacin, n-3 fatty acids and insulin resistance
    William Harris; Fiscal Year: 2007
    ..In recent studies from our laboratory, niacin and fish oil (n-3 fatty acids, FA) used in combination in individuals with the IRS improved the lipid phenotype, ..
  24. EVALUATING CORONARY LESION CHARGES USING NEURAL NETWORKS
    Stanley Azen; Fiscal Year: 1993
    CLAS, a randomized, controlled clinical trial testing niacin/colestipol plus diet therapy in non-smoking men with previous coronary bypass surgery, has demonstrated treatment benefits using both a) a coronary endpoint determination by a ..
  25. Monitoring Oxygen Repeatedly for Hypoxic Tumor Therapy
    Mohammad Khan; Fiscal Year: 2007
    ..If successful, this approach potentially could be immediately extended for clinical applications. [unreadable] [unreadable] [unreadable]..
  26. MECHANISMS OF ENZYMATIC REACTIONS
    PERRY FREY; Fiscal Year: 2006
    ..of epimerase will be to elucidate the molecular basis for the enhancement of the chemical reactivity of the niacin-coenzyme NAD+ by the use of binding energy between substrates and the enzyme...
  27. HDL AND PLAQUES--NOVEL MODELS AND IMAGING TECHNIQUES
    Edward Fisher; Fiscal Year: 2001
    ..Plasma lipid levels will be modified by therapy with a statin or statin plus niacin (to raise HDL) and changes in plaque size and composition will be followed serially by MRI...
  28. A TOPICAL MICRONUTRIENT DELIVERY SYSTEM
    Jaber Qasem; Fiscal Year: 2001
    ..A growing body of evidence demonstrates that micronutrients including vitamins B6, B12, C, E, folate, and niacin are involved in the maintenance of genomic integrity of skin cells via mechanisms ranging from scavenging ROS to ..
  29. Topical Micronutrient Delivery System
    Hyuntae Kim; Fiscal Year: 2005
    ..are to design, synthesize, characterize and evaluate the topical delivery properties of specific pronutrients (niacin, vitamin E, folate, Q1O, and lipoate) to evaluate the safety, tolerance, and efficacy, singly and in combinations ..
  30. A Transdermal Hypolipidemic Niacin Prodrug
    Hyuntae Kim; Fiscal Year: 2002
    b>Niacin has been used as first-line drug therapy for elevated serum cholesterol because of its broad efficacy on multiple lipid components as well as its low cost...
  31. OMEGA-3 FATTY ACIDS IN BIPOLAR DISORDER PROPHYLAXIS
    ANDREW STOLL; Fiscal Year: 2002
    ..Plasma and erythrocyte fatty acid content. 2. The niacin skin patch test (a possible marker of in vivo omega-3 fatty acid activity). 3...
  32. LIPOPROTEIN(A)-CHOLESTEROL ASSAY BY LECTIN PRECIPITATION
    LEO SEMAN; Fiscal Year: 1993
    ..Elevated Lp(a) levels can be treated with niacin. Lp(a) differs from other lipoproteins by the presence of a glycoprotein called apolipoprotein(a) [apo(a)], which ..
  33. BIOCHEMICAL PHARMACOLOGY OF NIACIN
    Jason Morrow; Fiscal Year: 1990
    Nicotinic acid (niacin) is a B vitamin with potent hypolipidemic effects. Niacin administration has been related to a reduction in coronary heart disease mortality and overall mortality after recovery from myocardial infarction...
  34. ATHEROSCLEROSIS PROGRESSION/REGRESSION IN MAN
    DAVID BLANKENHORN; Fiscal Year: 1990
    The existing project is a controlled atherosclerosis regression trial using either niacin/colestipol or placebo in men who have had coronary artery bypass surgery...
  35. EVALUATION OF TAURINE AND NIACIN IN LUNG FIBROSIS
    SHIRI GIRI; Fiscal Year: 1999
    ..The finding that dietary supplementation with taurine and niacin consistently, offers a marked protection against bleomycin (BL)-induced ILF in rodent models has opened a ..
  36. Does Raising HDL-C with Niacin Improve Endothelial Function in Early CKD?
    Vandana Menon; Fiscal Year: 2009
    ..b>Niacin is the most effective agent available to increase HDL-C levels and appears to improve endothelial function in non- ..
  37. Tuning-Up Human Metabolism
    Bruce Ames; Fiscal Year: 2005
    ..g. homocysteine accumulation in MTHFR: riboflavin; alcohol intolerance in half of Asians: niacin. 2) Testing the effectiveness of other metabolites and micronutrients...
  38. Targeting cofactor biosynthesis in biodefense pathogens
    Andrei Osterman; Fiscal Year: 2009
    ..In addition to setting the stage for the development of new antibiotics, this study will impact our understanding of an important class of key biosynthetic enzymes in the vitamin/cofactor metabolism of bacterial pathogens. ..
  39. Effects of Chromium on Progression of Insulin Resistance
    Peter Havel; Fiscal Year: 2006
    ..The results of these studies will provide valuable information for the design and implementation of new clinical studies examining the effects of chromium supplements in the management of metabolic syndrome in humans. ..
  40. NON INVASIVE MRI OF HUMAN VULNERABLE PLAQUE
    Valentin Fuster; Fiscal Year: 2001
    ..Plasma lipid levels will be modified by therapy with a statin or statin plus niacin (to raise HDL) and changes in plaque size and composition will be followed serially by MRI...
  41. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie M Ballantyne; Fiscal Year: 2010
    ....
  42. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2002
    ..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
  43. Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy
    Ashok Balasubramanyam; Fiscal Year: 2008
    ..fat mass and improve hormonal, metabolic and lipoprotein markers associated with insulin resistance; and 2) adding niacin, fenofibrate, or a combination of the two drugs to the intensive lifestyle intervention will result in further ..
  44. Postprandial Lipemia and Endothelial Function In ACCORD
    Henry Ginsberg; Fiscal Year: 2004
    ....
  45. Mentored Career Development in Patient Oriented Research
    Daniel Rader; Fiscal Year: 2006
    ..abstract_text> ..
  46. Gordon Research Conference: Lipoprotein Metabolism 2004
    Daniel Rader; Fiscal Year: 2004
    ....
  47. Mentored Clinical Research Scholar Program
    Henry Ginsberg; Fiscal Year: 2006
    ..They believe firmly that this K12 CRS Program will have an immense impact on the future of patient-oriented research in the next decades. [unreadable] [unreadable] [unreadable]..
  48. CELLULAR BASIS OF ANTIATHEROGENESIS BY APOLIPOPROTEIN E
    Daniel Rader; Fiscal Year: 2001
    ..These studies will provide greater understanding of the role of the local inflammatory response in atherosclerosis and its regulation by apoE. ..
  49. MOLECULAR & CLINICAL EVALUATION OF LOW HDL SYNDROMES
    Michael Miller; Fiscal Year: 2003
    ..Further understanding of the molecular basis of isolated low HDL-C and its potential clinical sequelae (e.g., CAD), may therefore aid in the development of therapeutic strategies to effectively treat this disorder. ..
  50. Perfluorocarbon Materials As Drug Delivery Vehicles
    Hans Joachim Lehmler; Fiscal Year: 2004
    ..abstract_text> ..
  51. MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
    Sergio Fazio; Fiscal Year: 2008
    ..These studies have the potential to uncover the basis for the therapeutic effect of HDL on the arterial plaque. [unreadable] [unreadable] [unreadable] [unreadable]..
  52. Distribution of PCB Atropisomers
    Hans Joachim Lehmler; Fiscal Year: 2008
    ..The long term career goal is to establish Dr. Lehmler as an investigator with independent research status and funding. ..
  53. Estrogen and Mechanisms of Cardiomyocyte Protection
    Richard Karas; Fiscal Year: 2009
    ....
  54. CAROTID PLAQUE COMPOSITION BY MRI DURING LIPID-LOWERING
    Xue Qiao Zhao; Fiscal Year: 2010
    ..The HDL target for the two niacin-treated groups is to increase 10 mg/dl from baseline...
  55. HDL metabolism: Influence of extracellular lipases
    Daniel Rader; Fiscal Year: 2009
    ....
  56. NUTRITION ACADEMIC AWARD
    Michael Miller; Fiscal Year: 2004
    ..Compliance with ATP II and JNC VI recommendations will also be assessed. In addition, medical students' diets and blood lipid levels will be assessed and tracked. ..
  57. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2004
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  58. P20-Mediated Suppression of Vascular Force
    Christopher Rembold; Fiscal Year: 2004
    ..Many current treatments target smooth muscle to reduce tone. It is possible that targeting the force suppression pathway (i.e. p20) might provide comparable benefits. ..
  59. NO-CGMP INHIBITION OF UROGENITAL SMOOTH MUSCLE
    Christopher Rembold; Fiscal Year: 2004
    ....
  60. MOLECULAR BASIS OF HIGH DENSITY LIPOPROTEIN DEFICIENCY
    ERNST SCHAEFER; Fiscal Year: 2009
    ..The results of this work will provide important insight into the contribution of allelic variation in the pathways of HDL metabolism, inflammation, and insulin resistance to the complex phenotype of low HDL-C. ..